久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • NewAmsterdam Pharma raises $196m through Series A funding round pharmaceutical-technology
    January 18, 2021
    Clinical stage company NewAmsterdam Pharma (NAP) has raised $196m (€160m) through Series A funding round to support the full Phase III development of its ApoB and LDL-c lowering small molecule drug, obicetrapib.
  • MSD’s CETP inhibitor cuts heart risk by 9 percent pharmatimes
    August 31, 2017
    MSD has revealed that its CETP inhibitor anacetrapib reduced the risk of major coronary events by 9 percent versus placebo in patients with cardiovascular disease already taking LDL-C lowering therapy alongside atorvastatin.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service